---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-041591"
form_type: "8-K"
ticker: "NUWE"
cik: "0001506492"
company_name: "Nuwellis, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:06:33.858328+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuwellis Q3 revenue $2.2M, down 6% YoY, up 29% sequentially; operating loss widens to $2.7M

## Summary
- Total revenue $2.2M, down 6% YoY but up 29% sequentially; pro-forma revenue grew ~7% YoY excluding one-time items.
- Gross margin 65.2% (down from 70% YoY); operating loss $2.7M vs $1.5M last year.
- Cash $3.1M at quarter end, debt-free; raised $1.9M via ATM facility.
- Launched new 24-hour circuit and dual-lumen catheter; first hospital-based outpatient therapies under new CMS code.
- Pediatric Vivian system accelerated with NIH funding; manufacturing transition to KDI Precision initiated.

## SEC filing metadata
- accession: 0001140361-25-041591
- form_type: 8-K
- ticker: NUWE
- cik: 0001506492
- company_name: Nuwellis, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/0001140361-25-041591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/ef20058643_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-041591
- JSON: https://secwatch.observer/filing/0001140361-25-041591.json
- Plain text: https://secwatch.observer/filing/0001140361-25-041591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.